Home
    Disclaimer
    25C-NBOMe molecular structure

    25C-NBOMe Stats & Data

    25c 2c-nbome Cimbi-82 2c-c-nbome Nbome-2c-c
    NPS DataHub
    MW335.83
    FormulaC18H22ClNO3
    CAS1227608-02-7
    IUPAC2-(4-chloro-2,5-dimethoxyphenyl)-~{N}-[(2-methoxyphenyl)methyl]ethanamine
    SMILESCOc1ccccc1CNCCc1cc(OC)c(Cl)cc1OC
    InChIKeyFJFPOGCVVLUYAQ-UHFFFAOYSA-N
    Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic

    History & Culture

    25C-NBOMe was discovered in 2003 by Ralf Heim at the Free University of Berlin. The compound was subsequently investigated by a research team at Purdue University led by David Nichols, and was first formally described in the scientific literature by Anders Ettrup and colleagues in 2010. Research interest in 25C-NBOMe has centered on its potential applications in neuroimaging. Scientists have studied its carbon-11 radiolabelled form as a ligand for mapping the distribution of serotonin 5-HT2A receptors in the brain using positron emission tomography (PET). The compound had virtually no history of recreational human use prior to 2010, when it first emerged on the online research chemical market. Its exceptional potency—approximately sixteen times that of its parent compound 2C-C—allows effective doses to fit onto blotter paper, similar to LSD. This characteristic has led to instances where 25C-NBOMe has been found on blotter mimics sold as LSD, contributing to safety concerns and prompting regulatory responses across numerous jurisdictions beginning in 2011.

    Subjective Effects

    Physical

    The physical effects of 25C-NBOMe can be broken down into several components which progressively intensify proportional to dosage.

    • Stimulation and Sedation: In terms of its effects on the subject's physical energy levels, 25C-NBOMe is considered to be energetic and well as sedating, leaving the subject in a state of equilibrium between being stationary and moving. The physical stimulation manifested by this substance can be described as similar to 2C-B, and is commonly experienced as simultaneously easygoing and physically difficult, sometimes presenting overstimulation which results in bodily shakes and teeth grinding. The levels of stimulation can be considered less intense than 25I-NBOMe and the sedation can be considered slightly less intense than other psychedelics such as Psilocin and 2C-C.
    • Sublingual numbing: Assuming the substance has been taken sublingually, the very first physical effect which a person will notice immediately after sublingual absorption is a strong, unpleasant metallic chemical taste. This is accompanied by a very obvious feeling of general numbness of the tongue and mouth which can stay for up to an hour after the blotter paper has been consumed. This is the key difference when it comes to determining whether your blotter paper contains LSD or one of the NBOMe series.
    • Temperature regulation loss
    • Spontaneous tactile sensations: The body high itself can be described as a generally mild, all-encompassing, soft but euphoric tingling sensation. This tingling sensation is also accompanied by spontaneous rushes of euphoria that become longer and more drawn out proportional to the dosage consumed.
    • Perception of decreased weight: In terms of the body's perceived weight, this substance consistently leaves people feeling extremely light, often to the point of total weightlessness.
    • Tactile hallucinations
    • Changes in gravity: Compared to classic tryptamines, this effect is considerably less intense than what is commonly experienced with DMT and Psilocin.
    • Nausea: As the tripper begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, but passes once this has either happened or the trip begins to fully set in. In comparison to other psychedelics such as psilocin, LSD, 2C-E and 2C-I, this could actually be very considered very mild in its intensity.
    • Vasoconstriction
    • Increased heart rate
    • Pupil dilation
    • Wakefulness
    • Increased blood pressure
    Cognitive

    The cognitive effects of 25C-NBOMe are described by many as remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.

    • Analysis enhancement: This component is consistently manifested only in the context of a non-social setting in which the user is alone and is introspection dominant.
    • Empathy, love and sociability enhancement: The entactogenic effects range from mild to powerful, but are inconsistently manifested. Entactogenic effects for people who try this substance usually become prominent in the presence of others. These feelings of increased sociability, love and empathy do not seem to be quite as strong or profound as those found within other entactogens (such as MDMA, 2C-B and AMT)
    • Thought acceleration
    • Time distortion
    • Immersion enhancement
    • Novelty enhancement
    • Conceptual thinking
    • Thought connectivity
    • Current mind state enhancement
    • Personal bias suppression
    • Memory suppression
    • Ego death
    Sensory
    Auditory
    • Enhancements
    • Distortions
    • Hallucinations
    Visual · Distortions
    • Drifting: (Melting, flowing, breathing and morphing) - In comparison to other psychedelics this effect can be described as highly detailed, slow and smooth in motion, static in their appearance and unrealistic/cartoon-like in style.
    • Tracers
    • After images
    • Symmetrical texture repetition
    • Colour shifting
    • Scenery slicing
    • Transformations
    • Environmental cubism
    • Diffraction
    Visual · Enhancements

    25C-NBOMe presents a full and complete array of possible visual enhancements.

    • Visual acuity enhancement
    • Colour enhancement
    • Pattern recognition enhancement
    Visual · Hallucinatory States

    25C-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 - 5 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT. This can be considered as on par with and identical in behaviour to that of LSD and 25I-NBOMe.

    • Transformations
    • Internal hallucinations: (Autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) These are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of religious, spiritual, mystical or a transcendental nature in their overall theme.
    • External hallucinations: (Autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots). These are often manifesting as rapidly moving, interactive solid and typically asymmetrical matter or physical beings reflecting imagined concepts. They are more common in bright environments and can be described as external in their manifestation, equally lucid and delirious in believability, interactive in style, autonomous in interaction, and almost exclusively alien, mystical, or a transcendental nature in their overall theme.

    Forked from Subjective Effect Documentation by Josie Kins, September 2015. Via dose.wiki (CC0).

    Toxicity

    PsychonautWiki

    25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it can be fatal at heavy dosages. It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing. It is strongly recommended that one use harm reduction practices when using this substance.

    Addiction & dependence

    25C-NBOMe is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating. Tolerance to the effects of 25C-NBOMe is built almost immediately after ingestion.

    Effect Profile

    Curated + 136 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10103.0
    Headspace Depth×3
    10102.2
    Auditory Effects×1
    10102.2
    Body Load / Somatic Effects×1
    108.85.2
    Catalog Erowid BlueLight

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Sublingual
    0-12 minutes
    30 minutes - 1.5 hours
    4-6 hours
    1-4 hours
    1-24 hours
    Total: 8-10 hours
    Insufflated
    45-90 minutes hours
    1-24 hours
    Total: 5-8 hours

    Community Effects

    TripSit
    Positive
    visual enhancement creativity
    Negative
    nausea vomiting body load

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    60% ●○○
    Psilocybin
    65% ●○○
    Psilocin
    65% ●○○
    Mescaline
    85% ●○○
    DMT
    65% ●○○
    5-MeO-DMT
    65% ●○○
    2C-B
    85% ●○○
    2C-E
    85% ●○○

    Experience Report Analysis

    Erowid BlueLight
    113 Reports
    2010–2015 Date Range
    107 With Age Data
    35 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 136 experience reports (113 Erowid + 23 Bluelight)

    136 Reports
    106 Effects Detected
    39 Positive
    46 Adverse
    21 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 39

    Music Enhancement 59.3% 70%
    Color Enhancement 57.3% 86%
    Euphoria 53.0% 88%
    Stimulation 39.7% 82%
    Empathy 32.4% 85%
    Surface Breathing 30.4% 82%
    Focus Enhancement 30.1% 78%
    Introspection 27.9% 80%
    Tactile Enhancement 27.2% 81%
    Body High 22.8% 85%
    Visual Trails 21.7% 86%
    Geometric Imagery 17.4% 84%
    Contentment 17.4% 79%
    Tingling 17.4% 86%
    Patterning 17.4% 89%
    Clarity 13.0% 82%
    Pain Relief 12.4% 70%
    Visual Sharpening 8.7% 82%
    Visual Clarity 8.7% 82%
    Auditory-Visual Synesthesia 8.7% 78%

    Adverse Effects 46

    Anxiety 58.1% 87%
    Confusion 31.6% 82%
    Body Load 30.4% 80%
    Fear 26.1% 90%
    Thought Disorganization 26.1% 81%
    Nausea 25.0% 85%
    Tremor 21.7% 77%
    Body Temperature Change 21.7% 81%
    Muscle Tension 13.9% 85%
    Thought Loops 13.2% 90%
    Insomnia 13.0% 83%
    Paranoia 13.0% 87%
    Panic 13.0% 95%
    Headache 11.8% 82%
    Increased Heart Rate 11.5% 70%
    Memory Suppression 11.0% 90%
    Pupil Dilation 11.0% 88%
    Sweating 9.5% 75%
    Jaw Clenching 8.8% 82%
    Paranoid Ideation 8.7% 90%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Common (n=25) Heavy (n=14)
    Visual Distortions 100.0% 92.9%
    Anxiety 68.0% 92.9%
    Color Enhancement 76.0% 71.4%
    Euphoria 72.0% 50.0%
    Music Enhancement 60.0% 64.3%
    Confusion 40.0% 50.0%
    Tactile Enhancement 24.0% 50.0%
    Introspection 36.0% 42.9%
    Empathy 32.0% 42.9%
    Auditory Effects 32.0% 42.9%
    Focus Enhancement 32.0% 42.9%
    Nausea 40.0% 35.7%
    Dissociation 36.0% 14.3%
    Body High 32.0% 35.7%
    Stimulation 32.0% 35.7%

    Subjective Effect Ontology

    Experience Reports

    Structured effect tags extracted from 136 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

    Visual

    visual distortions 108 79.4%

    1 unique effects extracted · Derived from Erowid & Bluelight reports

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 113 experience reports.

    Limited tier coverage — most reports fall within the Common / Heavy range. Effects at other dose levels may not be represented.

    Sublingual dose range: 300.0–600.0 µg (median 500.0 µg)
    Effect Common (n=25) Heavy (n=14)
    visual distortions
    100%
    93%
    anxiety
    68%
    93%
    color enhancement
    76%
    71%
    euphoria
    72%
    50%
    music enhancement
    60%
    64%
    confusion
    40%
    50%
    tactile enhancement
    24%
    50%
    introspection
    36%
    43%
    empathy
    32%
    43%
    auditory effects
    32%
    43%
    focus enhancement
    32%
    43%
    nausea
    40%
    36%
    dissociation
    36%
    14%
    body high
    32%
    36%
    stimulation
    32%
    36%
    closed-eye visuals
    24%
    36%
    open-eye visuals
    32%
    sedation
    24%
    29%
    hospital
    29%
    ego dissolution
    20%
    21%

    Showing top 20 of 33 effects

    Risk Escalation

    Sentiment Analysis

    Average frequency of positive vs adverse effects across dose tiers

    Common n=25
    11 positive 37.8% 10 adverse 24.4%
    Heavy n=14
    9 positive 48.4% 10 adverse 32.8%
    View effect breakdown

    Adverse Effects

    Effect Common (n=25) Heavy (n=14) Change
    Anxiety
    68%
    93%
    +36%
    Confusion
    40%
    50%
    +25%
    Nausea
    40%
    36%
    -10%
    Thought Loops
    16%
    21%
    +33%
    Muscle Tension
    16%
    21%
    +33%
    Memory Suppression
    8%
    21%
    +167%
    Jaw Clenching
    8%
    21%
    +167%
    Sweating
    21%
    0%
    Motor Impairment
    21%
    0%
    Seizure
    21%
    0%
    Headache
    20%
    0%
    Increased Heart Rate
    16%
    0%
    Pupil Dilation
    12%
    0%

    Positive Effects

    Effect Common (n=25) Heavy (n=14) Change
    Color Enhancement
    76%
    71%
    -6%
    Euphoria
    72%
    50%
    -30%
    Music Enhancement
    60%
    64%
    7%
    Tactile Enhancement
    24%
    50%
    +108%
    Introspection
    36%
    43%
    +19%
    Empathy
    32%
    43%
    +34%
    Focus Enhancement
    32%
    43%
    +34%
    Body High
    32%
    36%
    +11%
    Stimulation
    32%
    36%
    +11%
    Pain Relief
    12%
    0%
    Creativity Enhancement
    8%
    0%

    Dosage Distribution

    Dose distribution from experience reports

    Insufflated

    Median: 600.0 µg IQR: 400.0–1300.0 µg n=15

    Sublingual

    Median: 500.0 µg IQR: 300.0–600.0 µg n=15

    Real-World Dose Distribution

    62K Doses

    From 125 individual dose entries

    Sublingual (n=48)

    Median: 0.51mg 25th: 0.38mg 75th: 0.93mg 90th: 1.0mg
    mg/kg median: 0.006 mg/kg 75th: 0.012

    Insufflated (n=21)

    Median: 0.4mg 25th: 0.25mg 75th: 0.6mg 90th: 1.3mg
    mg/kg median: 0.006 mg/kg 75th: 0.012

    Oral (n=10)

    Median: 0.9mg 25th: 0.62mg 75th: 1.38mg 90th: 1.55mg
    mg/kg median: 0.016 mg/kg 75th: 0.024

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Oral

    Median: 0.024 mg/kg IQR: 0.011–0.034 mg/kg n=6

    Insufflated

    Median: 0.007 mg/kg IQR: 0.005–0.014 mg/kg n=15

    Sublingual

    Median: 0.006 mg/kg IQR: 0.004–0.007 mg/kg n=14

    Unknown

    Median: 0.01 mg/kg IQR: 0.006–0.014 mg/kg n=17

    Redose Patterns

    Redosing behavior across 100 reports

    14.0% Redosed
    1.2 Avg Doses
    180m Median Interval

    Legal Status

    Country Status Notes
    Austria Illegal (SMG) Prohibited since June 26, 2019 under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal.
    Brazil Controlled Listed on Portaria SVS/MS nº 344 as of February 18, 2014. The entire NBOMe series became controlled at this time, including 25I-, 25C-, 25D-, 25B-, 25E-, 25N-, 25P-, 25T2-, 25T7-, and 25H-NBOMe.
    Canada Schedule III (CDSA) Controlled as of October 31, 2016 as a derivative of 2,5-dimethoxyphenethylamine under the Controlled Drugs and Substances Act.
    China Controlled Classified as a controlled substance since October 2015.
    Czech Republic Banned Prohibited under national controlled substances legislation.
    Germany Anlage I BtMG Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited.
    Israel Controlled The NBOMe series became controlled in May 2013.
    Italy Schedule I Classified as a Schedule I controlled substance. Possession, distribution, and manufacture are illegal.
    Japan Narcotic Designated as a narcotic drug effective November 1, 2015.
    Latvia Schedule I Classified as a Schedule I controlled substance.
    New Zealand Class C analogue Considered substantially similar in chemical structure to the controlled hallucinogen DOB and therefore treated as a Class C controlled drug analogue. Withdrawn from sale in early 2012 following a statement by Associate Health Minister Peter Dunne.
    Russia Controlled The entire NBOMe series became controlled in October 2011, making Russia the first country to regulate this class of substances.
    Sweden Schedule I Added to Schedule I (substances without medical use) as of August 1, 2013, published in Medical Products Agency regulation LVFS 2013:15.
    Switzerland Controlled (Verzeichnis D) Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
    Turkey Illegal Classified as a controlled drug. Possession, production, supply, and import are prohibited.
    United Kingdom Class A Controlled as a Class A substance since June 2014 under the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971. Previously subject to a temporary class drug order from June 10, 2013.
    United States Schedule I Emergency scheduled by the DEA on November 15, 2013, along with 25B-NBOMe and 25I-NBOMe under the Controlled Substances Act. The temporary scheduling was extended in November 2015. Several states including Arkansas, Georgia, and Louisiana added it to their Schedule I lists prior to federal action. Scheduling also makes other NBOMe compounds probable Controlled Substance Analogues when intended for human consumption.
    ← Back to 25C-NBOMe